Eli Lilly & Co. closed 18.86% short of its 52-week high of $972.53, which the company reached on August 22nd.

Genomic medicine company Sangamo Therapeutics said it entered a license agreement with Eli Lilly, under which Lilly received rights to employ Sangamo's proprietary capsid, STAC-BBB, for up to five ...

Shares of Sangamo Therapeutics Inc (NASDAQ: SGMO) surged 30.2% following the announcement of a significant licensing agreement with pharmaceutical giant Eli Lilly and Company (NYSE: LLY ). The deal ...

UNICEF works to increase support and understanding of non-communicable diseases (NCDs) in childhood in low- and middle-income countries.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

“The 340B statute does not permit drug companies to unilaterally withhold discounts from 340B hospitals in exchange for the surrender of purchase data or what are, in essence, pre-payment audits. The ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

A retrospective review reports that pregnant women with pityriasis rosea onset before 15 weeks have higher rates of ...

The Kinsey Collection has been exhibited worldwide, and the family has raised more than $36 million for charitable causes, ...

Primary care company knownwell said on Wednesday it will provide health and weight-management services on Eli Lilly's ...

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...